<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622683</url>
  </required_header>
  <id_info>
    <org_study_id>2000026135</org_study_id>
    <nct_id>NCT04622683</nct_id>
  </id_info>
  <brief_title>Effects of Hepatic Ultrasound on Metabolic Homeostasis</brief_title>
  <official_title>Effects of Hepatic Ultrasound on Metabolic Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define the effect of ultrasound exposure of the liver in the&#xD;
      region of the porta hepatis on glucose homeostasis and insulin resistance in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>1 week</time_frame>
    <description>Change in OGTT measurements after Hepatic Ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Control Group- Healthy, Lean Individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.</description>
    <arm_group_label>Control Group- Healthy, Lean Individuals</arm_group_label>
    <arm_group_label>Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 60 years of age&#xD;
&#xD;
          -  Aim 1: Healthy lean men and women, BMI&lt;24 kg/m2, with normal fasting glucose (blood&#xD;
             glucose between 60 and 100mg/dl and normal glucose tolerance on OGTT (blood glucose&#xD;
             &lt;140 mg/dl at 2 hours post glucose challenge) at the screening visit.&#xD;
&#xD;
          -  Aim 2: Overweight and obese men and women, BMI 25 - 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 and type 2 diabetes&#xD;
&#xD;
          -  Surgery in the past 90 days&#xD;
&#xD;
          -  Previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or&#xD;
             liver&#xD;
&#xD;
          -  Recent traumatic injury, including intra-cerebral hemorrhage and visceral injury&#xD;
&#xD;
          -  End stage renal disease and/or uremia&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Previous leukemia and/or lymphoma&#xD;
&#xD;
          -  Human immunodeficiency virus infection or AIDS&#xD;
&#xD;
          -  Rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel&#xD;
             disease)&#xD;
&#xD;
          -  Arrhythmias, including but not limited to, atrial fibrillation, atrial flutter,&#xD;
             bradycardia, ventricular arrhythmias, and A-V block&#xD;
&#xD;
          -  Implanted pacemaker or cardioverter/defibrillator (AICD)&#xD;
&#xD;
          -  History of stable or unstable angina, myocardial infarction, angioplasty or coronary&#xD;
             arterial by-pass grafting surgery&#xD;
&#xD;
          -  History of stroke or TIA&#xD;
&#xD;
          -  History of deep venous thrombosis (DVT) and/or pulmonary embolism (PE)&#xD;
&#xD;
          -  Previous episodes of pancreatitis&#xD;
&#xD;
          -  Spinal disorders&#xD;
&#xD;
          -  Chronic pain syndromes&#xD;
&#xD;
          -  History of thrombosis or bleeding disorders&#xD;
&#xD;
          -  Stage III-IV pressure ulcers&#xD;
&#xD;
          -  Sickle cell anemia or other anemia syndromes&#xD;
&#xD;
          -  Monocytosis&#xD;
&#xD;
          -  Thrombocytopenia&#xD;
&#xD;
          -  Diagnosed with fever of unknown origin (FUO)&#xD;
&#xD;
          -  Previously or currently implanted vagus nerve stimulator&#xD;
&#xD;
          -  Previously or currently implanted spinal cord stimulator&#xD;
&#xD;
          -  Other chronically-implanted electronic medical device&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Individuals who have taken any of the following medications within two weeks of&#xD;
             receiving ultrasound delivery: anti-coagulant, anti-platelet, anti-inflammatory,&#xD;
             immunosuppressive agents, alpha and/or beta adrenoceptor blocking agents, anti-seizure&#xD;
             medications, anti-diabetic medication&#xD;
&#xD;
          -  Individuals with a substance abuse problem&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Ascites detected in the abdomen that may effect delivery of shear wave elastroghapy&#xD;
             pulse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Herzog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janice Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Prinz</last_name>
    <phone>203-785-5977</phone>
    <email>jacqueline.prinz@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Prinz</last_name>
      <phone>203-785-5977</phone>
      <email>jacqueline.prinz@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Raimund Herzog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwartz GJ. Roles for gut vagal sensory signals in determining energy availability and energy expenditure. Brain Res. 2018 Aug 15;1693(Pt B):151-153. doi: 10.1016/j.brainres.2018.04.004. Review.</citation>
    <PMID>29903617</PMID>
  </reference>
  <reference>
    <citation>Cotero V, Fan Y, Tsaava T, Kressel AM, Hancu I, Fitzgerald P, Wallace K, Kaanumalle S, Graf J, Rigby W, Kao TJ, Roberts J, Bhushan C, Joel S, Coleman TR, Zanos S, Tracey KJ, Ashe J, Chavan SS, Puleo C. Noninvasive sub-organ ultrasound stimulation for targeted neuromodulation. Nat Commun. 2019 Mar 12;10(1):952. doi: 10.1038/s41467-019-08750-9. Erratum in: Nat Commun. 2020 Mar 9;11(1):1336.</citation>
    <PMID>30862827</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

